MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- AUROBINDO PHARMA - DIVIS LABORATORIES
AUROBINDO PHARMA vs DIVIS LABORATORIES - Comparison Results
AUROBINDO PHARMA Change
Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
DIVIS LABORATORIES 
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
Current Valuations
| AUROBINDO PHARMA | DIVIS LABORATORIES | AUROBINDO PHARMA/ DIVIS LABORATORIES |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 16.8 | 49.9 | 33.6% | View Chart |
| P/BV | x | 3.6 | 13.4 | 27.2% | View Chart |
| Dividend Yield | % | 0.3 | 0.5 | 63.3% |
Financials
 AUROBINDO PHARMA  DIVIS LABORATORIES |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AUROBINDO PHARMA Mar-19 |
DIVIS LABORATORIES Mar-19 |
AUROBINDO PHARMA/ DIVIS LABORATORIES |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 830 | 1,639 | 50.6% | |
| Low | Rs | 527 | 1,115 | 47.3% | |
| Sales per share (Unadj.) | Rs | 333.9 | 186.3 | 179.2% | |
| Earnings per share (Unadj.) | Rs | 40.4 | 51.0 | 79.2% | |
| Cash flow per share (Unadj.) | Rs | 51.8 | 57.3 | 90.3% | |
| Dividends per share (Unadj.) | Rs | 2.50 | 16.00 | 15.6% | |
| Dividend yield (eoy) | % | 0.4 | 1.2 | 31.7% | |
| Book value per share (Unadj.) | Rs | 237.1 | 261.8 | 90.6% | |
| Shares outstanding (eoy) | m | 585.91 | 265.47 | 220.7% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.0 | 7.4 | 27.5% | |
| Avg P/E ratio | x | 16.8 | 27.0 | 62.2% | |
| P/CF ratio (eoy) | x | 13.1 | 24.0 | 54.6% | |
| Price / Book Value ratio | x | 2.9 | 5.3 | 54.4% | |
| Dividend payout | % | 6.2 | 31.4 | 19.7% | |
| Avg Mkt Cap | Rs m | 397,569 | 365,592 | 108.7% | |
| No. of employees | `000 | 17.9 | 11.8 | 150.7% | |
| Total wages/salary | Rs m | 25,849 | 5,423 | 476.7% | |
| Avg. sales/employee | Rs Th | 10,956.9 | 4,175.1 | 262.4% | |
| Avg. wages/employee | Rs Th | 1,447.7 | 457.7 | 316.3% | |
| Avg. net profit/employee | Rs Th | 1,324.3 | 1,141.8 | 116.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 195,636 | 49,463 | 395.5% | |
| Other income | Rs m | 1,553 | 1,556 | 99.8% | |
| Total revenues | Rs m | 197,189 | 51,019 | 386.5% | |
| Gross profit | Rs m | 39,519 | 18,718 | 211.1% | |
| Depreciation | Rs m | 6,680 | 1,689 | 395.5% | |
| Interest | Rs m | 2,626 | 35 | 7,502.9% | |
| Profit before tax | Rs m | 31,767 | 18,551 | 171.2% | |
| Minority Interest | Rs m | 27 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
| Tax | Rs m | 7,269 | 5,023 | 144.7% | |
| Profit after tax | Rs m | 23,645 | 13,527 | 174.8% | |
| Gross profit margin | % | 20.2 | 37.8 | 53.4% | |
| Effective tax rate | % | 22.9 | 27.1 | 84.5% | |
| Net profit margin | % | 12.1 | 27.3 | 44.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 153,645 | 46,501 | 330.4% | |
| Current liabilities | Rs m | 120,429 | 8,468 | 1,422.2% | |
| Net working cap to sales | % | 17.0 | 76.9 | 22.1% | |
| Current ratio | x | 1.3 | 5.5 | 23.2% | |
| Inventory Days | Days | 135 | 131 | 103.4% | |
| Debtors Days | Days | 64 | 86 | 74.2% | |
| Net fixed assets | Rs m | 103,909 | 25,797 | 402.8% | |
| Share capital | Rs m | 586 | 531 | 110.4% | |
| "Free" reserves | Rs m | 138,322 | 68,962 | 200.6% | |
| Net worth | Rs m | 138,908 | 69,493 | 199.9% | |
| Long term debt | Rs m | 1,800 | 0 | - | |
| Total assets | Rs m | 264,544 | 80,383 | 329.1% | |
| Interest coverage | x | 13.1 | 531.0 | 2.5% | |
| Debt to equity ratio | x | 0 | 0 | - | |
| Sales to assets ratio | x | 0.7 | 0.6 | 120.2% | |
| Return on assets | % | 9.9 | 16.9 | 58.9% | |
| Return on equity | % | 17.0 | 19.5 | 87.4% | |
| Return on capital | % | 23.8 | 26.7 | 89.1% | |
| Exports to sales | % | 49.6 | 0 | - | |
| Imports to sales | % | 18.8 | 24.6 | 76.2% | |
| Exports (fob) | Rs m | 97,091 | NA | - | |
| Imports (cif) | Rs m | 36,741 | 12,187 | 301.5% | |
| Fx inflow | Rs m | 97,316 | 41,238 | 236.0% | |
| Fx outflow | Rs m | 40,589 | 12,405 | 327.2% | |
| Net fx | Rs m | 56,727 | 28,833 | 196.7% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 16,220 | 9,543 | 170.0% | |
| From Investments | Rs m | -28,768 | -6,854 | 419.7% | |
| From Financial Activity | Rs m | 19,191 | -2,459 | -780.3% | |
| Net Cashflow | Rs m | 6,656 | 230 | 2,899.1% | |
Share Holding
| Indian Promoters | % | 54.1 | 52.0 | 104.0% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 8.0 | 11.8 | 67.4% | |
| FIIs | % | 27.7 | 19.0 | 145.8% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 10.2 | 17.2 | 59.3% | |
| Shareholders | 69,601 | 31,796 | 218.9% | ||
| Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: STRIDES PHARMA SCIENCE ELDER PHARMA ALEMBIC ALEMBIC PHARMA CADILA HEALTHCARE
Compare AUROBINDO PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
A Time Correction in the Nifty(Momentum Moves)
The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.
Related Views on News
DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)
Feb 10, 2021 | Updated on Feb 10, 2021For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)
Sep 15, 2020 | Updated on Sep 15, 2020For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)
Jun 8, 2020 | Updated on Jun 8, 2020For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
Gold 65,000 and Silver 84,000 in 2022
Feb 26, 2021In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
AUROBINDO PHARMA SHARE PRICE
Mar 5, 2021 (Close)
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA 8-QTR ANALYSIS
COMPARE AUROBINDO PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.